Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.

Analysis revealed that myeloid-supporting cytokines such as IL-3, GM-CSF, and FLT3L were secreted during the CART-123 therapy, promoting AML blast survival via kinase signaling. This cytokine ...

APCs migrate to the local-regional lymph node and present a peptide to T cells in a more efficient manner than the AML blasts itself. These lymphocytes become activated and proliferate.

Findings suggested that the BB305 LVV vector was present in the AML blast cells, but there was not sufficient information to determine causality. Vector insertion in the AML cells from this ...

which is a compelling target for AML due to its overexpression on leukemic stem cells and AML blasts. This antibody-like recombinant protein therapeutic is designed to engage both leukemic cells ...

HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA Paris, April 23, 2025, 6.45pm CET AB Science SA (Euronext - FR0010557264 - AB) announces ...

A dual targeting activating CAR (aCAR) that recognizes both CD33 and FLT3 tumor antigens improves the anti-tumor activity, ensuring the targeting of AML blasts and LSCs. Currently, the drug is in ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk ...

AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high ...